Abstract:Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA The receptor tyrosine kinase RON, a member of the MET family, is critical in epithelial tumorigenesis. RON also is a validated drug target for cancer therapy due to its high levels of expression in cancer cells. At present, monoclonal antibodies (mAb) and tyrosine kinase inhibitors have been developed, preclinically tested, and evaluated under clinical trials. However, accumulated evidences have indicated that the efficacy of RON-targeted therapy alone is weak. Thus, there is an urgent need to develop a strategy to improve the effectiveness of RON-targeted cancer therapy. Here we report the development and therapeutic efficacy of anti-RON mAb Zt/g4-maytansinoid conjugates (Zt/g4-DM1) with enhanced cytotoxicity against colorectal cancer cells (CRC) in mouse xenograft tumor models. Zt/g4 (IgG1a/κ) was selected among several anti-RON mAbs as the drug carrier for its ability to induce RON endocytosis in CRC cells. Zt/g4 was conjugated to DM1 via the thioether link to form anti-RON antibody-drug conjugate Zt/g4-DM1 with an antibody-drug ratio of 1:4 molecules. Using HCT116, HT29, and SW620 cells as the model, we found that Zt/g4-DM1 retains the intrinsic activity that causes rapid RON internalization. Targeted payload delivery significantly induced cell cycle arrest at G2/M phase, reduced cell viability with IC50 values at ∼1.2 μg/ml, which resulted in massive cell death within a period of 72h. The cytotoxic effect of Zt/g4-DM1 was negligible in cancer cells with minimal RON expression. Studies from the mouse CRC xenograft model revealed that Zt/g4-DM1 is highly effective in delaying HT29 cell-mediated tumor growth in athymic nude mice. In a single cycle of q 4 days x 5 with Zt/g4-DM1 at 1, 3, 7, 10, and 15 mg/kg body weight, we observed significant tumor inhibition (>70% tumor growth delay) when Zt/g4-DM1 was used at 7 mg/kg. Significantly, more than 95% of tumor growth was inhibited at 10 mg/kg or 15 mg/kg of Zt/g4-DM1. Continued observation after last treatment showed that the inhibitory effect of Zt/g4-DM1 is long lasting up to 20 days without signs of tumor regrowth. The prepared Zt/g4-DM1 is stable in vitro and has a minimal toxic effect in vivo when Zt/g4-DM1 was used below 40 mg/kg. Zt/g4 has been sequenced and a 3D model of antigen-binding domains in variable regions in both heavy and light chains has been created. Zt/g4 is currently under humanization for potential clinical trials. In conclusion, Zt/g4-DM1 is a highly effective biotherapeutics for inhibition of CRC growth in mouse xenograft models. The therapeutic potential of Zt/g4-DM1 provides a novel strategy for targeted CRC therapy in the future. Moreover, the development of humanized Zt/g4-DM1 opens an avenue for testing its therapeutic effect on various types of cancers harboring aberrant RON expression. (This project is support in part by NIH grant CA91980 to MHW). Citation Format: Ming-Hai Wang, Liang Feng, Hang-Ping YAO, Wei Wang, Sharad Sharma, Ruiwen Zhang. Anti-RON antibody-drug maytansinoid conjugates (Anti-RON ADC) as potential biotherapeutics for targeted colorectal cancer therapy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-269. doi:10.1158/1538-7445.AM2014-LB-269

Abstract LB-269: Anti-RON antibody-drug maytansinoid conjugates (Anti-RON ADC) as potential biotherapeutics for targeted colorectal cancer therapy

Preclinical Evaluation Of Anti-Ron Antibody-Drug Maytansinoid Conjugates (Anti-Ron Adc) For Targeted Colorectal Cacner Therapy.

Targeting RON Receptor Tyrosine Kinase for Treatment of Advanced Solid Cancers: Antibody–drug Conjugates As Lead Drug Candidates for Clinical Trials

Therapeutic Evaluation of Monoclonal Antibody-Maytansinoid Conjugate As a Model of RON-targeted Drug Delivery for Pancreatic Cancer Treatment.

The Monoclonal Antibody Zt/f2 Targeting RON Receptor Tyrosine Kinase As Potential Therapeutics Against Tumor Growth-Mediated by Colon Cancer Cells

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials.

Supplementary Table 1 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-Ron ADC) As a Novel Therapeutics for Targeted Colorectal Cancer Therapy

Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.

Development of A Novel RON Targeted Antibody‐Drug Conjugates Using Cysteine Bridging Technology for Potential Treatment of Pancreatic Cancer

Supplementary Figure 2 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-Ron ADC) As a Novel Therapeutics for Targeted Colorectal Cancer Therapy

Reduced RON Expression, DM1 resistance and MRP1 Upregulation Contributes to Resistance in Colon Cancer Cells against anti-RON Antibody-Drug Conjugate Zt/g4-DM1

Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Monoclonal Antibody (Mab)-Induced Down-Regulation of RON Receptor Tyrosine Kinase Diminishes Tumorigenic Activities of Colon Cancer Cells

Development Of A Novel Ron Receptor Targeted Antibody-Drug Conjugates Using Cysteine Bridging Technology For Potential Treatment Of Pancreatic Cancer

Data from RON Receptor Tyrosine Kinase As a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE

Supplementary Figure 5 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-Ron ADC) As a Novel Therapeutics for Targeted Colorectal Cancer Therapy

Erratum To: Biological Evaluation of Antibody-Maytansinoid Conjugates As a Strategy of RON Targeted Drug Delivery for Treatment of Non-Small Cell Lung Cancer

Supplementary Figure 1 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-Ron ADC) As a Novel Therapeutics for Targeted Colorectal Cancer Therapy

Supplementary Table 3 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-Ron ADC) As a Novel Therapeutics for Targeted Colorectal Cancer Therapy

Monoclonal antibody (mAb)-induced down-regulation of the RON receptor tyrosine kinase impairs malignant phenotypes of colon cancer cells

RON Receptor Tyrosine Kinase in Tumorigenic Stemness As a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells.